CMS' final decision on PET beta-amyloid coverage will impede progress in dementia imaging and treatment, and it sends a discouraging message across the field of nuclear medicine and molecular imaging, argues SNMMI President-elect Dr. Peter Herscovitch. While the decision memo contains some positive changes, the ruling is largely disappointing, Herscovitch said, because it puts the test out of reach for many. "If the scans are not available to patients, and by and large they won't be if they're not covered by Medicare because they are quite expensive, then we feel the care of patients with cognitive decline and possible Alzheimer's disease won’t be as good as it would otherwise be," he said.

Related Summaries